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Abstract 
Farnesylated prelamin A is a processing
intermediate produced in the lamin A matura-
tion pathway. Accumulation of a truncated far-
nesylated prelamin A form, called progerin, is a
hallmark of the severe premature ageing syn-
drome, Hutchinson-Gilford progeria. Progerin
elicits toxic effects in cells, leading to chro-
matin damage and cellular senescence and
ultimately causes skin and endothelial defects,
bone resorption, lipodystrophy and accelerated
ageing. Knowledge of the mechanism underly-
ing prelamin A turnover is critical for the
development of clinically effective protein
inhibitors that can avoid accumulation to toxic
levels without impairing lamin A/C expression,
which is essential for normal biological func-
tions. Little is known about specific molecules
that may target farnesylated prelamin A to elic-
it protein degradation. Here, we report the dis-
covery of rapamycin as a novel inhibitor of
progerin, which dramatically and selectively
decreases protein levels through a mechanism
involving autophagic degradation. Rapamycin
treatment of progeria cells lowers progerin, as
well as wild-type prelamin A levels, and rescues
the chromatin phenotype of cultured fibrob-
lasts, including histone methylation status and
BAF and LAP2a distribution patterns.
Importantly, rapamycin treatment does not
affect lamin C protein levels, but increases the
relative expression of the prelamin A endopro-
tease ZMPSTE24. Thus, rapamycin, an antibi-
otic belonging to the class of macrolides, previ-
ously found to increase longevity in mouse
models, can serve as a therapeutic tool, to
eliminate progerin, avoid farnesylated
prelamin A accumulation, and restore chro-
matin dynamics in progeroid laminopathies.
Introduction
Hutchinson-Gilford progeria syndrome
(HGPS) is an autosomal dominant condition
which develops in the first or second year of
life, followed by severe and rapid premature
senescence, which involves almost all tis-
sues.1,2 Patients present delayed growth, short
stature, alopecia, thinning of skin, loss of sub-
cutaneous fat, midface hypoplasia, skeletal
involvement with osteolysis and fractures, pre-
mature atherosclerosis, cardiac failure leading
to death or stroke at about 13.5 years. A de
novo missense mutation in exon 11 leads to
creation of an abnormal splice donor site that
results in expression of a truncated, perma-
nently farnesylated prelamin A, termed prog-
erin.3,4 This is the most common mutation in
HGPS. Toxicity of progerin has been well docu-
mented in several papers.5-7 Lowering progerin
levels or eliminating its expression has been
shown to ameliorate the cellular phenotype
both in mouse and human cell models.5,8
Moreover, accumulation of wild-type farnesy-
lated prelamin A as a secondary effect of prog-
erin expression, worsens the cellular pheno-
type.9-11 In the reported study, we explored the
possibility that rapamycin, an antibiotic
belonging to the class of macrolides, known to
activate autophagy in cells through inactiva-
tion of the inhibitory mTOR-dependent path-
way, could trigger progerin degradation.12 Our
results show that rapamycin treatment of
HGPS cells dramatically and selectively
reduces progerin and prelamin A levels and
elicits rescue of LAP2a, BAF and trimethylated
H3K9 organisation, thus improving the chro-
matin epigenetic status.
Materials and MethodsCell cultures and transfection
HGPS skin fibroblasts were obtained from a
6-year-old patient carrying the G608G LMNA
mutation. Control skin fibroblast cultures were
obtained from skin biopsies of healthy patients
(mean age 12) undergoing orthopaedic surgery,
following a written consent. The protocol had
been approved by the local ethical committee
and informed consent had been obtained from
patients or families. Cell cultures had been
established and cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal
calf serum (FCS) and antibiotics. The experi-
ments were performed at passages 5-10.
Transient transfections of HEK 293T cells were
performed by calcium phosphate method. FLAG-
tagged plasmids contained wild-type prelamin A
(LA-WT) or prelamin A Δ50 (LA-Δ50), encoding
a form devoid of the 50 aminoacids lacking in
the progerin sequence.11 After transfection,
cells were incubated for 72 h.Drug treatments 
Rapamycin (1 μM, Sigma, Milano, Italy) was
applied to cultured fibroblasts  for 6 days. This
drug inhibits mTOR activity and releases the
autophagic signaling pathway, which is inhib-
ited by mTOR.13 In transfected HEK 293 cells,
rapamycin was applied at 2 μM concentration
for 72 h. To block lysosomal activity, chloro-
quine (Sigma, 25 μM for 10 h) was applied
either in the presence or in the absence of
rapamycin. To check proteasome-mediated
degradation the ubiquitin proteasome inhbitor
MG132 (1 μM for 10 h) was applied. Antibodies 
Antibodies employed for Western blot analy-
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sis or immunofluorescence labeling were:
anti-lamin A/C, goat polyclonal (SC-6215, used
at 1:1000 dilution for the Western blot analysis,
Santa Cruz Biotechnology Inc., Segrate, MI,
Italy); anti-prelamin A, goat polyclonal (SC-
6214 used at 1:100 dilution for the immunoflu-
orescence analysis, Santa Cruz); anti-prelamin
A, rabbit polyclonal (antibody 1188-2,
Diatheva, Fano, Italy), raised against the last
15 aminoacids of the prelamin A sequence
including the farnesylated cysteine residue but
not the SIM sequence;14 anti-LAP2a, rabbit
polyclonal;15 anti-trimethyl-H3K9, rabbit poly-
clonal (Upstate, Lake Placid, NY, USA); anti-
emerin, mouse monoclonal (Monosan, Uden,
The Netherlands); anti-BAF, rabbit polyclonal
(FL-89, Santa Cruz); anti-LC3 rabbit polyclonal
antibody (ABR, Pierce); anti-FLAG, mouse
monoclonal (M2, Sigma); anti-actin, goat poly-
clonal (Santa Cruz).Western blot analysis
Western blot analysis was done as follows.
Cells were lysed in lysis buffer containing 20
mM Tris-HCl, pH 7.0, 1% Nonidet P-40, 150 mM
NaCl, 10% glycerol, 10 mM EDTA, 20 mM sodi-
um fluoride, 5 mM sodium pyrophosphate, 1
mM Na3VO4, 1 mM PMSF, 10 μg/mL leupeptin
and 10 μg/ml pepstatin at 4°C. Cell lysates
were diluted in Laemmli buffer, subjected to
SDS-PAGE (8%) and transferred to nitrocellu-
lose membrane. Membranes were saturated
with 4% BSA and incubated with primary anti-
bodies for 1 h at room temperature. Secondary
antibodies were used at 1:10000 dilution for 30
min. Immunoblotted bands were revealed by
the Amersham ECL detection system. Intensity
measurement was performed using a BioRad
densitometer (GS 800) equipped with Quantity
One Software.Gene expression analysis
Total RNA was isolated using Rneasy Mini
Kit (Qiagen GmbH, Hilden, Germany) from
confluent fibroblast cultures following manu-
facturer instructions. RNA was reverse tran-
scribed into cDNA using the High Capacity
cDNA Reverse Transcription Kit (Applied
Biosystems, Monza, Italy). LMNA or ZMPSTE24
expression was evaluated by Real Time PCR,
performed using an Applied Biosystems
StepOne termal cycler instrumentation
(Applied Biosystems), by amplifying 1 μg of
cDNA and the TaqMan Gene Expression Assays
(Applied Biosystems). Probes and primers
obtained by Applied Biosystems were: GAPDH,
assay ID Hs99999905_m1, LMNA, assay ID
Hs00153462_m1*, ZMPSTE24, assay ID
Hs00195298_m1*. The amplification protocol
was: 50°C for 2 min; 95°C for 10 min; 95°C for
15 s, 60°C for 1 min, for 40 cycles. The results
were calculated by the 2 ΔΔ-CT method16 or as
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Figure 1. Rapamycin reduces progerin level in HGPS cells. A) Western blotting evaluation
of lamin A/C and progerin in control (CONTROL) and Hutchinson Gilford progeria
cells (HGPS). Whole lysates from control and HGPS cells untreated (-) or treated (+) with
rapamycin (Rapamycin), MG132 or chloroquine-diphosphate (Cq) were subjected to
lamin A/C, LC3-B2 and actin antibodies detection; B) densitometric analysis of lamin A
and C immunolabeled bands detected in control fibroblasts; C) densitometric analysis of
lamin A and C immunolabeled bands detected in HGPS fibroblasts; P=0.0358 for lamin
A (rapa), P=0.0298 for lamin A (Mg); D) densitometric analysis of progerin immunoblot-
ted bands; P=0.0390 for progerin (rapa); P=0.0458 for progerin (Mg); E) prelamin A,
FLAG and LC3-B2 protein levels evaluation in HEK-293 cells expressing FLAG-tagged
wild type prelamin A (LA-WT) or progerin (LA-Δ50). Immunolabeled bands observed in
untreated (-) or rapamycin (Rapamycin) and chloroquine-diphosphate (Cq) treated (+)
cells are shown; F) densitometric of FLAG immunoblotted bands; G) RT-PCR analysis of
ZMPSTE24 and LMNA mRNA expression in untreated (Nt) and rapamycin-treated
HGPS cells (Rapa) and control (control); 2 -ΔΔCT values are reported relative to untreated
control samples. P=0.0236 for LA-Δ50 (rapa); H) ratio between ZMPSTE24 and LMNA
mRNA expression. Values are means of duplicate experiments ± S.D. In B, C, D and F
densitometric analysis of triplicate experiments was performed, and the mean values ±
S.D. are reported; asterisk indicates statistically significant difference with respect to
lamin A or progerin densitometry in untreated samples; statistical significance was calcu-
lated by the Mann-Whitney test vs untreated HGPS samples, or cells expressing LMNA
constructs. 
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ratio between gene of interest and GAPDH ref-
erence gene.17 The experiments were per-
formed in duplicate. Immunofluorescence 
Human fibroblasts grown on coverslips were
fixed with 4% paraformaldehyde at 4°C for 10
min and permeabilized with 0.15% Triton X-
100 for 5 min. Alternatively, cells were fixed
with absolute methanol at -20°C. Samples
were incubated with PBS containing 4% BSA
to saturate non-specific binding and incubated
with primary antibodies overnight at 4°C, and
with secondary antibodies for 1 h at room tem-
perature. Anti-prelamin A Sc-6214, anti-lamin
A/C and anti-trimethyl H3K9 were used at
1:100 dilution. Anti-prelamin A 1188-2 and
anti-BAF were applied at 1:10 dilution. Anti-
LAP2a was applied at 1:300 dilution. Slides
were mounted with an anti-fade reagent in
glycerol and observed with a Nikon E 600 fluo-
rescence microscope equipped with a digital
camera. Statistical analysis
Statistical analysis was performed using the
non-parametric Mann-Whitney U test.18
Experiments were done in triplicate and differ-
ences were considered statistically significant
for P<0.05.
ResultsRapamycin treatment of HGPSfibroblasts 
In order to test rapamycin effect on prelamin
A in laminopathic cells, we treated cultured
fibroblasts with rapamycin for 6 days. HGPS
nuclei accumulate the truncated prelamin A
form, known as progerin, obtained by aberrant
splicing of the LMNA gene due to the G608G
mutation. In HGPS cells, progerin levels were
strikingly reduced following administration of
rapamycin (Figure 1A). Progerin was not
degraded under basal conditions, as shown by
absence of CQ or MG132-induced protein accu-
mulation, showing that the protein minimally
undergoes spontaneous degradation (Figure 1
A-D). 
Transfection of HEK293 cells with an LMNA
construct encoding progerin (LA-Δ50) was
performed to support the above reported data
(Figure 1E). Rapamycin treatment for 72 h
strongly reduced LA-Δ50 level, while CQ
administration did not cause protein accumu-
lation (Figure 1E), supporting the finding that
progerin does not undergo degradation in
untreated cells. Quantitative analysis also sup-
ported the results showing progerin degrada-
tion by rapamycin (Figure 1 D,F). Importantly,
accumulation of LC3-B2, which is a marker of
autophagic activity, was observed in HGPS
cells and, to a lower extent, in HEK293 cells
expressing progerin, before rapamycin trea-
ment, but was increased by rapamycin treat-
ment (Figure 1 A,E). The latter finding sug-
gested that activation of the authophagic sig-
naling is triggered by progerin itself.
RT-PCR analysis of LMNA or ZMPSTE24
mRNA was performed in HGPS before and after
rapamycin treatment. LMNA and ZMPSTE24
expression were not decreased by rapamycin
treatment, demonstrating that progerin elimi-
nation does not occur through downregulation
of mRNA expression (Figure 1G). Figure 1H
shows that the ratio between ZMPSTE24 and
LMNA expression is increased following treat-
ment, suggesting that not only degradation of
progerin, but also processing of wild-type
prelamin A is potentially  increased by drug
treatment.Nuclear envelope in rapamycintreated cells 
To test whether rapamycin could affect other
nuclear envelope constituents, besides
prelamin A, control and HGPS cells were exam-
ined before and after drug treatment. Figure 2
shows the western immunoblot of lamin B1,
lamin B2, emerin, BAF and LAP2a (Figure 2A).
Rapamycin treatment did not affect protein
levels in control or laminopathic fibroblasts
(Figure 2A). However, in HGPS fibroblasts,
where LAP2a was downregulated, rapamycin
administration restored protein levels compa-
rable to controls (Figure 2 A,B). These results
suggested that reduction of progerin and pos-
sibly wild-type prelamin A levels could restore
nuclear integrity in HGPS cells. Progerin and chromatin-bindingproteins in rapamycin-treated cells
To support this hypothesis, progerin,  farne-
sylated prelamin A and chromatin-binding
prelamin A partners were examined by
immunofluorescence before and after
rapamycin treatment (Figure 2 C-H). Progerin
and farnesylated prelamin A were detected at
the nuclear rim of HGPS fibroblasts, but not in
controls (Figure 2 C-F). Rapamycin dramati-
cally reduced progerin and farnesylated
prelamin A levels (Figure 2 D-F).  Importantly,
rapamycin treatment did not modify lamin A/C
level and localization, thus confirming that
lamin C is not substantially affected by
rapamycin (Figure 2 E,F). Next, the expression
pattern of the prelamin A-binding protein
LAP2a was examined. LAP2a was evenly dis-
tributed in the nucleoplasm of control fibrob-
lasts, but was mislocalized to the nuclear
periphery in HGPS fibroblasts (Figure 2 C,D).
Rapamycin restored both LAP2a level (Figure
2 A,B) and the proper distribution of LAP2a
throughout the nucleoplasm (Figure 2 C,D).
Next, the effect of rapamycin treatment on the
localization of the prelamin A and chromatin-
binding protein BAF, was assessed. BAF was
recruited to the nuclear envelope in lamino-
pathic cells,11 while in a major proportion of
control cells it was located in the cytoplasm
and, to a lower amount in the nucleus (Figure
2 G,H). Treatment with rapamycin, restored
the proper distribution of BAF in HGPS cells
(Figure 2 H).  Chromatin organization is recovered in rapamycin treatedlaminopathic cells 
The above reported recovery of LAP2a and
BAF expression patterns obtained by
rapamycin treatment, suggested that loss of
heterochromatin, which is known to occur in
HGPS cells could have been similarly rescued.
The methylation status of histone H3 lysine 9
(H3K9) was determined by specific labeling of
the trimenthylated lysine. We had previously
shown altered methylation pattern of H3K9 in
HGPS cells.5 Here, we could observe recovery of
trimethyl- H3K9 distribution pattern in
rapamycin-treated HGPS nuclei (Figure 3).
Fluorescence intensity measurement showed
that trimethylated H3K9 levels were strongly
reduced in HGPS nuclei; morevover, the clus-
tered distribution of the histone observed in
control cells (Figure 3 A,B) was completely lost
(Figure 3 C,D). Trimethyl-H3K9 was not affect-
ed by rapamycin treatment in control cells
(Figure 3 E,F). However, the proper organiza-
tion and expression level of trimethyl-H3K9
was restored by rapamycin treatment of HGPS
cells (Figure 3 G,H,I), which indicated recovery
of heterochromatin organization. Thus, we
conclude that rapamycin may be effectively
used to restore the chromatin phenotype in
lamino pathies.
Discussion
The study here reported shows that activa-
tion of the mTOR-dependent authophagic
pathway using rapamycin can counteract prog-
erin and farnesylated prelamin A accumulation
in HGPS cells, leading to rescue of the chro-
matin phenotype of senescent cells. 
The toxicity of farnesylated prelamin A and
progerin is well established.5,14,19-21 Several
studies have shown that reduction of prelamin
A or progerin levels either by molecular
approaches6,8 or by drug treatment5,21 improves
the cellular phenotype in progeroid cells. Here,
we used a well-known drug, rapamycin, which
Original paper
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Figure 2. Nuclear envelope/lamina proteins in rapamycin treated cells. A) Western Blotting analysis of LAP2a (LAP2), lamin B1 (lamin
B1), lamin B2 (lamin B2), emerin (emerin) and Barrier-to-autointegration factor (BAF) in control (control) and HGPS cells (HGPS)
untreated (-) or treated (+) with rapamycin. Actin was detected as protein loading control. Immunolabeled bands are shown; B) densit-
ometric analysis of LAP2a immunolabeled bands detected in Western blotting analysis performed in control and HGPS untreated (-)
or rapamycin treated cells (+). Asterisk indicates statistically significant difference, P=0.0319 for HGPS + rapamycin (+) vs untreated
HGPS (-); C) prelamin A and LAP2a immunofluorescence labeling performed in untreated (-) or rapamycin  treated (+) control cells.
Prelamin A was evaluated using a goat-polyclonal antibody visualized by TRITC-conjugated secondary antibody (red). LAP2a distri-
bution was evaluated using a rabbit-polyclonal antibody visualized by FITC-conjugated secondary antibody (green); D) progerin and
LAP2a immunolabeling detection performed in untreated (-) or rapamycin treated (+) HGPS cells. Progerin (progerin) detection was
performed using a mouse-monoclonal antibody visualized by Cy3-conjugated secondary antibody (red). LAP2a distribution was eval-
uated using a rabbit-polyclonal antibody visualized by FITC-conjugated secondary antibody (green). In untreated HGPS cells progerin
staining was observed, while LAP2a labeling was decreased. Rapamycin treatment dramatically reduced progerin labeling and restored
LAP2 a staining levels; E) Lamin A/C and farnesylated-prelamin A detection performed in untreated (-) or rapamycin treated (+) con-
trol cells. Lamin A/C  (lamin A/C) was evaluated using a goat-polyclonal antibody visualized by TRITC-conjugated secondary antibody
(red). Farnesylated-prelamin A  (F-prelamin A) staining was performed using a rabbit-polyclonal antibody visualized by FITC-conjugat-
ed secondary antibody (green). Lamin A/C was detected in untreated or treated cells at the same levels. F-prelamin A was  undetected in
both samples; F) Lamin A/C and farnesylated-prelamin A detection performed in untreated (-) or rapamycin treated (+) HGPS cells.
Lamin A/C (lamin A/C) was evaluated using a goat-polyclonal antibody visualized by TRITC-conjugated secondary antibody (red).
Farnesylated-prelamin A  (F-prelamin A) staining was performed using a rabbit-polyclonal antibody visualized by FITC-conjugated sec-
ondary antibody (green). Lamin A/C staining was observed at the nuclear lamina of both untreated and treated cells. F-prelamin A stain-
ing observed in untreated cells was strongly reduced by rapamycin treatment; G) prelamin A BAF detection performed in untreated (-)
or rapamycin treated (+) control cells. Prelamin A was stained by a goat-polyclonal antibody visualized by TRITC-conjugated second-
ary antibody (red). BAF immunolabeling detection was performed by a rabbit-polyclonal antibody visualized by FITC-conjugated sec-
ondary antibody (green). Prelamin A was undetectable in untreated or rapamycin treated cells. BAF showed a normal cellular distribu-
tion in both samples; H) prelamin A and Barrier-to-autointegration (BAF) detection was performed in untreated (-) or rapamycin treat-
ed (+) HGPS cells. Prelamin A was stained by a goat-polyclonal antibody visualized by TRITC-conjugated secondary antibody (red).
BAF was labeled by rabbit-polyclonal antibody and visualized by FITC-conjugated secondary antibody (green). Prelamin A staining was
present at the nuclear lamina of untreated cells while in rapamycin treated cells lamin A precursor was undetectable. BAF nuclear local-
ization was observed in HGPS untreated cells. The normal BAF nucleo-cytoplasmic cellular distribution was recovered by rapamycin
treatment. In panel C, D, E, F,G and H nuclei were counterstained with DAPI. Scale bar, 10 µm.
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interferes with m-TOR inhibition of
autophagy, thus triggering the authophagic
pathway.13 Authophagy is a physiological
degradation mechanism, mostly aimed at scav-
enging damaged organelles, but also implied
in the elimination of altered proteins.13 Our
results show a major role of lysosomal degrada-
tion in the reduction of prelamin A levels trig-
gered by rapamycin, as demonstrated by the
effective accumulation of progerin, following
cloroquine inhibition of rapamycin-treated
cells.  Moreover, our study shows that degrada-
tion of progerin does not occur at detectable
levels in untreated cells. Thus, toxicity of prog-
erin, which is likely associated with aberrant
intermolecular interactions mediated by the
farnesylated C-terminus of the molecule,11,22 is
further increased by the resistance to degrada-
tion of that prelamin A form. 
In this scenario, the availability of a drug
capable of triggering farnesylated prelamin A
degradation paves the way to promising thera-
peutic perspectives. Activation of authophagy
by prelamin A accumulation has been report-
ed23 and it is supported by our evidence of LC3-
B2 accumulation24 in untreated HGPS cells, as
well as by electron microscopy studies (not
shown). However, since progerin is not or min-
imally degraded in untreated HGPS fibroblasts,
while undergoes degradation upon rapamycin
stimulus, we suggest that the function of
rapamycin in laminopathic cells is to target
progerin and farnesylated prelamin A to
degrading enzymes. This event could be medi-
ated by the prelamin A-specific C-terminus,
since lamin C appears to be substantially unaf-
fected by drug treatment. In this context, we
speculate that a physiological role of prelamin
A processing could be to provide a pool of far-
nesylated lamin A precursors to be either
degraded or processed to mature protein,
depending on the cell requirement. The unex-
pected finding that the relative amount of
ZMPSTE mRNA is increased in rapamycin-
treated cells, suggests that not only prelamin A
degradation, but also prelamin A processing
may be enhanced by drug treatment. In this
context, the restoring ability of rapamycin we
describe in HGPS may be extended to the treat-
ment of other laminopathies featuring accu-
mulation of farnesylated prelamin A forms dif-
ferent from progerin.
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